Summary & Overview
HCPCS J9381: Injection, teplizumab-mzwv, 5 mcg
HCPCS Level II code J9381 denotes an injection of teplizumab-mzwv, 5 mcg. As a HCPCS Level II drug code, it identifies a specific biologic product administered in outpatient settings and billed as a drug line item. Nationally, precise coding for biologics like teplizumab-mzwv matters for claims accuracy, patient access, and payer contracting because it affects reimbursement, utilization tracking, and prior authorization workflows.
Key payers addressed in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise briefing on clinical context and service settings, payer coverage considerations, common modifiers used with HCPCS drug codes, and guidance on where to locate payer policies and billing guidance. The publication summarizes benchmarks for drug billing and utilization where available and flags typical administrative steps payers expect for biologic drug claims, such as NDC reporting, route and site of service documentation, and applicable prior authorization requirements.
This overview is intended for revenue cycle, pharmacy, and clinical administrative audiences seeking a national perspective on billing and coding practices for teplizumab-mzwv using HCPCS Level II code J9381.
Billing Code Overview
HCPCS Level II code J9381 represents the drug injection teplizumab-mzwv, specified as 5 mcg per billing unit. The service type is injectable biologic drug administration. The typical site of service for this billing code is outpatient clinic or hospital outpatient infusion center, where drug products administered by intravenous or subcutaneous injection are billed as pharmacy or drug line items.
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient is a 12–17 year old with newly diagnosed stage 1 type 1 diabetes mellitus at high risk of progression, or an individual identified with multiple autoantibodies and preserved C-peptide, referred to an endocrinology specialty clinic for disease-modifying therapy. The clinician orders J9381 (injection, teplizumab-mzwv, 5 mcg) as part of a multi-dose induction and maintenance regimen. The patient presents to an outpatient infusion center or hospital-based infusion clinic staffed by an endocrinologist, pediatric endocrinologist, or infusion nurse. Pre-infusion workflow includes verification of diagnosis, informed consent, baseline vital signs, documentation of current medications and allergies, review of prior laboratory results (including complete blood count and liver function tests), and establishment of IV access or subcutaneous administration per product labeling.
During each administration visit, the medication is prepared by pharmacy with appropriate lot tracking and compound labeling; the dose is confirmed against the patient’s weight and the product strength. The nurse administers J9381 per protocol, monitors for infusion reactions and vital sign changes for the recommended observation period, and documents the administration time, dose, lot number, route, and any adverse events. Follow-up visits include serial monitoring of clinical response, glucose control, and routine safety labs. Billing uses J9381 units based on the vial strength and institutional billing guidance, and may include applicable modifiers for unusual circumstances or payer-specific requirements.
Coding Specifications
| Modifier | Description |
|---|